- Home
- RLGT vs PVLA Comparison
RLGT vs PVLA Comparison
Compare RLGT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- PVLA
- Stock Information
- Founded
- RLGT 2001
- PVLA 2015
- Country
- RLGT United States
- PVLA United States
- Employees
- RLGT N/A
- PVLA N/A
- Industry
- RLGT Oil Refining/Marketing
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- RLGT Consumer Discretionary
- PVLA Health Care
- Exchange
- RLGT Nasdaq
- PVLA Nasdaq
- Market Cap
- RLGT 280.5M
- PVLA 285.2M
- IPO Year
- RLGT N/A
- PVLA N/A
- Fundamental
- Price
- RLGT $6.49
- PVLA $54.15
- Analyst Decision
- RLGT
- PVLA Strong Buy
- Analyst Count
- RLGT 0
- PVLA 11
- Target Price
- RLGT N/A
- PVLA $56.64
- AVG Volume (30 Days)
- RLGT 78.1K
- PVLA 133.4K
- Earning Date
- RLGT 09-12-2025
- PVLA 08-14-2025
- Dividend Yield
- RLGT N/A
- PVLA N/A
- EPS Growth
- RLGT 173.51
- PVLA N/A
- EPS
- RLGT 0.35
- PVLA N/A
- Revenue
- RLGT $888,148,000.00
- PVLA N/A
- Revenue This Year
- RLGT $14.45
- PVLA N/A
- Revenue Next Year
- RLGT $5.76
- PVLA N/A
- P/E Ratio
- RLGT $18.47
- PVLA N/A
- Revenue Growth
- RLGT 7.18
- PVLA N/A
- 52 Week Low
- RLGT $5.44
- PVLA $11.17
- 52 Week High
- RLGT $7.94
- PVLA $57.19
- Technical
- Relative Strength Index (RSI)
- RLGT 64.16
- PVLA 67.56
- Support Level
- RLGT $6.38
- PVLA $49.13
- Resistance Level
- RLGT $6.50
- PVLA $57.19
- Average True Range (ATR)
- RLGT 0.14
- PVLA 4.30
- MACD
- RLGT 0.04
- PVLA 0.15
- Stochastic Oscillator
- RLGT 92.31
- PVLA 81.32
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.